Associations of Predicted CVD risk by the PREVENT Equation with AI-analyzed Coronary Atherosclerotic Plaque Characteristics
Abstract Body (Do not enter title and authors here): Background The PREVENT equations estimates 10-year total CVD risk using clinical and laboratory data. Its association with coronary plaque morphology using coronary CT angiography (CCTA) remains unclear. Moreover, it is unknown whether lipoprotein(a) [Lp(a)], an established marker of cardiovascular risk, provides additional predictive value for coronary plaque burden beyond that offered by the PREVENT equations. Objective Assess the association between predicted 10-year total CVD risk and coronary plaque features, and evaluate whether Lp(a) adds predictive value. Methods We conducted a retrospective study, asymptomatic patients without prior cardiovascular events underwent coronary computed tomography angiography (CCTA) between 2018 and 2024. Coronary plaque characteristics were quantified using artificial intelligence (AI)-based analysis. One-way ANOVA was used to assess differences in plaque burden across risk categories using the 10-year total predicted CVD based on the PREVENT equations: low risk (<5%), borderline risk (5-7.4%), intermediate risk (7.5-19.9%), and high risk (≥20%). We used linear regression to assess associations between 10-year total predicted CVD risk and total plaque volume (TPV), calcified plaque (CP), non-calcified plaque (NCP), and low-density non-calcified plaque (LDNCP). Lp(a), modeled per 50 nmol/L, was then added to a model that included 10-year predicted total CVD risk to assess its contribution beyond the PREVENT score. Results The cohort included 525 adults with a mean age of 55.8 years; 30% were female; and 51% were taking a statin. Total, calcified and non-calcified plaque burden, stenosis severity, and remodeling index increased across higher 10-year total CVD risk categories (p<0.001 for trend; Figure 1). LDNCP was not associated with 10-year total CVD risk. When analyzing the PREVENT score as a continuous variable, higher scores were associated with greater TPV, CP, and NCP (all p<0.001, Table 1), but not LDNCP (p=0.15). Higher Lp(a) was associated with TPV, CP, and NCP after adjustment for 10-year total CVD risk (Table 1). Conclusion The 10-year predicted total CVD risk estimated by the PREVENT equations was associated with coronary plaque burden, including calcified and non-calcified components. These results support estimating 10-year predicted total CVD risk using the PREVENT equations as a tool for subclinical atherosclerosis risk assessment and highlight the relevance of Lp(a) in identifying residual plaque risk.
Gurevitz, Chen
( Mount Sinai Health
, New York
, New York
, United States
)
Fisher, Rebecca
( Mount Sinai Health
, New York
, New York
, United States
)
Muntner, Paul
( University of Alabama at Birmingham
, Birmingham
, Alabama
, United States
)
Fisher, Edward
( Mount Sinai Health
, New York
, New York
, United States
)
Rosenson, Robert
( Mount Sinai Health
, New York
, New York
, United States
)
Author Disclosures:
Chen Gurevitz:DO NOT have relevant financial relationships
| Rebecca Fisher:DO NOT have relevant financial relationships
| Paul Muntner:DO have relevant financial relationships
;
Consultant:Merck:Active (exists now)
; Consultant:Novartis:Active (exists now)
; Research Funding (PI or named investigator):Amgen Inc.:Active (exists now)
| Edward Fisher:No Answer
| Robert Rosenson:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Amgen:Active (exists now)
; Consultant:Intercept Pharmaceuticals:Past (completed)
; Consultant:Eli Lilly:Active (exists now)
; Consultant:Editas Medicine:Past (completed)
; Consultant:CRISPER Therapeutics:Past (completed)
; Consultant:Arrowhead:Active (exists now)
; Consultant:Amgen:Active (exists now)
; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now)
; Research Funding (PI or named investigator):89Bio:Active (exists now)
; Research Funding (PI or named investigator):Novo Nordisk:Past (completed)
; Research Funding (PI or named investigator):Novartis:Active (exists now)
; Research Funding (PI or named investigator):NIH:Active (exists now)
; Research Funding (PI or named investigator):Merck:Active (exists now)
; Research Funding (PI or named investigator):Eli Lilly:Active (exists now)
; Research Funding (PI or named investigator):Arrowhead:Active (exists now)